Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
10.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
26.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
12.05. | This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday | 19 | Benzinga.com | ||
12.05. | Boral Capital starts NeuroSense stock with Buy, $14 target | 12 | Investing.com | ||
07.05. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
24.04. | NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update | 140 | PR Newswire | Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about... ► Artikel lesen | |
09.04. | NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment | 259 | PR Newswire | New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.
CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/... ► Artikel lesen | |
08.04. | NeuroSense Therapeutics GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
07.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
07.04. | NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates | 136 | PR Newswire | Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline
Ongoing partnership... ► Artikel lesen | |
07.04. | NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
27.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
25.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 25.03.2025 | 502 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.03.2025
Aktien
1 US50125G1094 KULR Technology Group... ► Artikel lesen | |
19.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
19.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
18.12.24 | NeuroSense Provides Business Update and Third Quarter 2024 Financial Results | 189 | PR Newswire | CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing... ► Artikel lesen | |
11.12.24 | NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC | 179 | PR Newswire | The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025
... ► Artikel lesen | |
28.10.24 | NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission | 166 | PR Newswire | Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success
Parallel... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CARDIOL THERAPEUTICS | 0,918 | -4,77 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
CIDARA THERAPEUTICS | 53,00 | -0,93 % | Guggenheim erhöht Kursziel für Cidara Therapeutics nach FDA-Fortschritten | ||
AVIDITY BIOSCIENCES | 46,230 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
180 LIFE SCIENCES | 10,270 | 0,00 % | 180 Life Sciences setzt auf Ethereum - Milliardenwechsel in Geschäftsstrategie | Die 180 Life Sciences Corp. (Börsenkürzel: ATNF) hat bekanntgegeben, inzwischen 82.186 Ether-Token zu halten - ein Bestand, der zum 11. August 2025 rund 349 Millionen US-Dollar wert war. Der durchschnittliche... ► Artikel lesen | |
BEAM THERAPEUTICS | 16,860 | 0,00 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down | ||
HARMONY BIOSCIENCES | 35,470 | 0,00 % | Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence | ||
SUMMIT THERAPEUTICS | 25,680 | 0,00 % | Evercore ISI hebt Kursziel für Summit Therapeutics auf 34 US-Dollar an | ||
EVOTEC | 6,670 | +1,37 % | Dieses Biotech-Unternehmen schlägt Bayer, Evotec, Novo Nordisk & Co. um Längen! | Während Anlegerinnen und Anleger verzweifelt auf einen Turnaround der Aktien von Bayer, Evotec und Novo Nordisk warten, liefert dieser Rivale konstant Gewinne. Anstatt auf Verlierer sollten Anlegerinnen... ► Artikel lesen | |
JANUX THERAPEUTICS | 24,270 | 0,00 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
STRUCTURE THERAPEUTICS | 18,740 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
SIGA TECHNOLOGIES | 9,300 | 0,00 % | SIGA Technologies - A solid quarter for topline growth | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 10,380 | 0,00 % | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | ||
VALNEVA | 4,400 | +10,72 % | Valneva: FDA gibt Chikungunya-Impfstoff IXCHIQ wieder frei | Valneva hat bekanntgegeben, dass die US-Arzneimittelbehörde FDA die zuvor empfohlene Einschränkung für den Chikungunya-Impfstoff IXCHIQ bei Personen ab 60 Jahren aufgehoben hat. Zugleich wurde eine... ► Artikel lesen | |
NURIX THERAPEUTICS | 10,020 | 0,00 % | Nurix Therapeutics: Günstiger BTK-Player | In der Welt der Biotechnologie zählt die gezielte Zerstörung krankheitsverursachender Proteine zu den innovativsten Ansätzen der modernen Arzneimittelforschung. Nurix Therapeutics, ein Unternehmen mit... ► Artikel lesen |